{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:13:40Z","timestamp":1790745220323,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T00:00:00Z","timestamp":1647216000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>This study aimed to determine durability of sustained virologic response (SVR) in hepatitis C virus\u2010infected participants treated with glecaprevir\u2010 and\/or pibrentasvir\u2010containing regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>M13\u2010576, a rollover study, evaluated the durability of SVR in a follow\u2010up period of approximately 3\u00a0years after hepatitis C virus genotype 1\u20136\u2010infected participants received a glecaprevir\u2010 and\/or pibrentasvir\u2010containing regimen in previous phase 2\/3 clinical trials. The primary efficacy endpoint was the percentage of participants maintaining SVR and the percentage of participants experiencing relapse or reinfections. Resistance\u2010associated substitutions and safety outcomes related to liver progression were also assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 384 participants enroled, 377 participants were included in the as\u2010observed population and 287 participants completed the study. In prior studies, 99.7% (376\/377) of participants achieved SVR12; of those, an observed 99.5% (374\/376) and 100% (286\/286) completing the study, maintained SVR. After non\u2010responder imputation of missing data, 286\/376 participants (76%) maintained SVR. The participant previously not achieving SVR was a treatment\u2010experienced male with compensated cirrhosis who had NS3 and NS5A substitutions at enrolment, which remained detectable for 12\u00a0months. Of the two participants not maintaining SVR, one was re\u2010infected and one experienced late relapse at post\u2010treatment week 60. Five participants (all with a fibrosis stage \u2265F3) had hepatocellular carcinoma. No events were deemed related to glecaprevir\/pibrentasvir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Glecaprevir\/pibrentasvir demonstrated long\u2010term durability of efficacy after SVR12 was achieved. Hepatic\u2010related decompensation events were not seen. Owing to low incidence of virologic failure, conclusions were not drawn on persistence of resistance\u2010associated substitutions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/liv.15211","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T04:13:45Z","timestamp":1645935225000},"page":"1278-1286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Durability of sustained virological response to glecaprevir\/pibrentasvir and resistance development: A long\u2010term follow\u2010up study"],"prefix":"10.1111","volume":"42","author":[{"given":"Fred","family":"Poordad","sequence":"first","affiliation":[{"name":"The Texas Liver Institute University of Texas Health  San Antonio Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Felizarta","sequence":"additional","affiliation":[{"name":"Private Practice  Bakersfield California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty B.","family":"Yao","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Scott","family":"Overcash","sequence":"additional","affiliation":[{"name":"eStudySite  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[{"name":"Southern California GI and Liver Centers and Southern California Research Center  Coronado California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosh","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Institute of Liver Studies Kings College Hospital NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-7955","authenticated-orcid":false,"given":"Edward","family":"Gane","sequence":"additional","affiliation":[{"name":"New Zealand Liver Transplant Unit University of Auckland  Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shaw","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital  Adelaide South Australia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Waters","sequence":"additional","affiliation":[{"name":"eStudySite  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Topp","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[{"name":"AbbVie Inc  North Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology University Hospital KULeuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,14]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization.Global hepatitis report 2017. Accessed 12 July 2021.https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789?sequence=1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62401-6"},{"issue":"1","key":"e_1_2_11_5_1","first-page":"31","article-title":"Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma","volume":"51","author":"Leone N","year":"2005","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0274"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2011.03.006"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.12.028"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.03.004"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.039"},{"issue":"2","key":"e_1_2_11_12_1","first-page":"154","article-title":"Concordance of sustained virologic response at weeks 4, 12 and 24 post\u2010treatment of hepatitis c in the era of new oral direct\u2010acting antivirals: a concise review","volume":"15","author":"Burgess SV","year":"2016","journal-title":"Ann Hepatol"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12273"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-10-199711150-00003"},{"key":"e_1_2_11_15_1","unstructured":"AbbVie.Mavyret[US Package insert]. North Chicago IL."},{"key":"e_1_2_11_16_1","unstructured":"AbbVie.Maviret EU [Summary of Product Characteristics] 2020. Accessed 20 October 2020.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/maviret\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29541"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy220"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.020"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30046"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1687823"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153694"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ396"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001316"},{"key":"e_1_2_11_30_1","unstructured":"AASLD\u2010IDSA.Glecaprevir\/Pibrentasvir Treatment Failures. Recommendations for testing managing and treating hepatitis C. Accessed 7 December 2021.https:\/\/www.hcvguidelines.org\/treatment\u2010experienced\/g\u2010p\u2010failures"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12932"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3253"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01249-18"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2011.08.015"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15211","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.15211","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.15211","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T07:43:48Z","timestamp":1692863028000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.15211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,14]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/liv.15211"],"URL":"https:\/\/doi.org\/10.1111\/liv.15211","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,14]]},"assertion":[{"value":"2021-08-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}